The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
Phones:
+7 (495) 482-4118
+7 (495) 482-4329
  • Toll-free number for subscriptions:
    +8 800 250-18-12
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Nasonov E.L.

"Research Institute of rheumatology n. a. V. A. Nasonova"

Prospects for rheumatoid arthritis pharmacotherapy: New opportunities and recommendations

Authors:

Nasonov E.L.

More about the authors

Journal: Therapeutic Archive. 2016;88(12): 4‑10

DOI: 10.17116/terarkh201688124-10

Read: 6966 times

Contact the author
Table of contents

PROSPECTS FOR RHEUMATOID ARTHRITIS PHARMACOTHERAPY: NEW OPPORTUNITIES AND RECOMMENDATIONS
PROSPECTS FOR RHEUMATOID ARTHRITIS PHARMACOTHERAPY: NEW OPPORTUNITIES AND RECOMMENDATIONS

To cite this article:

Nasonov EL. Prospects for rheumatoid arthritis pharmacotherapy: New opportunities and recommendations. Therapeutic Archive. 2016;88(12):4‑10. (In Russ.)
https://doi.org/10.17116/terarkh201688124-10

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Mechanism of action of various therapies for viti­ligo. Pharmacologist’s and dermatovenerologist’s perspective. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(6):734-741
Chro­nic pain and multimorbidity. Russian Journal of Pain. 2026;(1):72-81
Stra­tegies for the treatment of gout: control of hype­ruricemia and prevention of complications. Russian Journal of Preventive Medi­cine. 2026;(3):109-115
Ecto­pic pregnancy in the inte­rstitial fallopian tube. Russian Bulletin of Obstetrician-Gynecologist. 2026;(3):55-59
A clinical case of a combination of rheumatoid arthritis that debu­ted with the deve­lopment of bronchiectasis. Journal of Respiratory Medi­cine. 2026;(2):56-60
Comparison of various psoriasis treatment methods. Russian Journal of Clinical Dermatology and Vene­reology. 2026;(3):436-442
Abstract:

The paper considers a current strategy, international and Russian recommendations for the pharmacotherapy of rheumatoid arthritis (RA), one of the most common and severe human immune-mediated inflammatory diseases. It emphasizes the need for early diagnosis and therapy with disease-modifying antirheumatic drugs, primarily methotrexate (MT), starting at the onset of the disease, and careful monitoring of therapeutic effectiveness, allowing RA remission to be achieved with a treatment-to-target strategy. The author discusses recent RA pharmacotherapy advances that are related to the rational use of MT, biological agents, and the new targeted JAK inhibitor tofacitinib.

Keywords:

rheumatoid arthritis
methotrexate
disease-modifying antirheumatic drugs
biological agents

Authors:

Nasonov E.L.

"Research Institute of rheumatology n. a. V. A. Nasonova"

Close metadata

References:

  1. Nasonov E.L., Karateev D.E., Balabanova R.M. Revmatoidnyi artrit. V knige «Revmatologiya. Natsional'noe rukovodstvo» pod redaktsiei E.L. Nasonova, V.A. Nasonovoi. Moskva: GEOTAR-Media; 2008.
  2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. New Engl Med. 2012; 365:2205-2219. doi: 10.1056/NEJMra1004965
  3. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016. doi: 10.1016/S)140-6736(16)30173-7
  4. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita. Pod redaktsiei E.L. Nasonova. Moskva: IMA-PRESS; 2013.
  5. Sokka T, Pincus T. Rheumatoid arthritis: strategy more important than agent. Lancet. 2009;374:430-432. doi: 10.1016/S0140-6736(09)61432-X
  6. Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol. 2015. doi: 10.1038/nrrheum.2015.8
  7. Smolen JS, Aletaha D, Bijsma JWJ et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target:recommendations of an international task force. Ann Rheum Dis. 2010;69:631-637. doi:10.1136/ard.2009.123919
  8. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target:2014 update the recommendations of an international task force. Ann Rheum Dis. 2016;75:305. doi:10.1136/annrheumdis-2015-207524
  9. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs:2013 update. Ann Rheum Dis. 2014;73:492-509. doi:10.1136/annrheumdis-2013-204573
  10. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheum. 2016;68:1-26. doi:10.1002/art.39489
  11. Nasonov EL, Mazurov VI, Karateev DE i dr. Proekt rekomendatsii po lecheniyu revmatoidnogo artrita Obshcherossiiskoi obshchestvennoi organizatsii «Assotsiatsiya revmatologov Rossii — 2014 (chast' 1). Nauchno-prakticheskaya revmatologiya. 2014;52:477-494. doi: 10.14412/1995-4484-2014-477-494
  12. Nasonov EL, Karateev DE, Chichasova NV. Rekomendatsii EULAR po lecheniyu revmatoidnogo artrita — 2013: obshchaya kharakteristika i diskussionnye problemy. Nauchno-prakticheskaya revmatologiya. 2013;51:609-622. doi:10.14412/1995-4484-2013-609-22
  13. Nasonov EL. Metotreksat pri revmatoidnom artrite — 2015: novye fakty i idei. Nauchno-prakticheskaya revmatologiya. 2015;53:421-433. doi:10.14412/1995-4484-2015-64-76
  14. Nasonov EL, Karateev DE, Chichasova NV. Novye rekomendatsii po lecheniyu revmatoidnogo artrita (EULAR, 2013):mesto metotreksata. Nauchno-prakticheskaya revmatologiya 2014;52:8-26. doi:10.14412/1995-4484-2015-32-50
  15. Popkova TV, Novikova DS, Gasparyan AY, Nasonov EL. Cardiovascular effects of methotrexate in rheumatoid arthritis. Curr Med Chem. 2015;22:1903-1910. doi:10.2174/0929867322666150415122039
  16. Kremer JM. Can methotrexate prevent knee arthroplasties in patients with rheumatoid arthritis. J Rheumatol. 2015;42:2217-2218. doi:http://www.jrheum.org/content5/42/12/2217
  17. Karateev DE, Luchikhina EL, Demidova NV. i dr. Primenenie podkozhnoi formy metotreksata dlya lecheniya bol'nykh aktivnym revmatoidnym artritom (issledovanie REMARKA). Nauchno-prakticheskaya revmatologiya. 2016;54:138-144. doi: 10.14412/1995-4484-2016-138-144
  18. Murav'ev YuV, Gridneva GI, Karateev DE, Luchikhina EL. Bezopasnost' primeneniya metotreksata v forme rastvora dlya podkozhnykh in"ektsii u bol'nykh revmatoidnym artritom. Nauchno-prakticheskaya revmatologiya. 2015;53:371-374. doi:10.14412/1995-4484-2015-371-374
  19. Duran J, Bockorny M, Dalasl D, LaValley M, Felson DT. Methotrexate dosage as a source of bias in biological trials in rheumatoid arthritis:a systemic review. Ann Rheum Dis. 2016;75:1595-1598. doi:10.1136/annrheumdis-2016-209383
  20. Nasonov EL, Karateev DE, Satybaldyev AM, i soavt. Revmatoidnyi artrit v Rossiiskoi Federatsii po dannym Rossiiskogo registra bol'nykh artritom (soobshchenie I). Nauchno-prakticheskaya revmatologiya. 2015;53:472-484. doi:10.14412/1995-4484-2015-472-484
  21. Nasonov EL. Novye rekomendatsii po lecheniyu revmatoidnogo artrita (EULAR, 2013) — mesto glyukokortikoidov. Nauchno-prakticheskaya revmatologiya. 2015;53:238-250. doi:10.14412/1995-4484-2015-238-250
  22. Strehl C, Bijlsma JW, de Wit M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptable low level of harm to facilitate implementation of existing recommendations:viewpoimts from an EULAR task force. Ann Rheum Dis. 2016;75:952-957. doi:10.1136/annrheumdis-2015-208916
  23. Boyman O, Comte D, Spertini F. Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol. 2014;10:612-627. doi:10.1038/nrrheuum.2014.123
  24. Murav'ev YuV, Murav'eva LF. Nesvoevremennye mysli o primenenii genno-inzhenernykh biologicheskikh preparatov pri revmaticheskikh boleznyakh. Nauchno-prakticheskaya revmatologiya. 2015;53:371-374. doi:10.14412/1995-4484-2016-361-366
  25. National Institute for Health and Care Excellence (UK). Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed [online], (2016).
  26. Hazlewood GS, Barnabe C, Tomilison G, Marshall D, Devoe D, Bombardier C. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systemic review and network meta-analysis. BMJ. 2016;353:i1777. doi:10.1136/bmj.i1777
  27. Espinosa F, Fabre S, Pers Y-M. Remission-induction therapies for early rheumatoid arthritis:evidence to date and clinical implications. Ther Adv Musculoskelet Dis. 2016;8:107-118. doi:10.1177/175920X16654476
  28. Schett G, Emery P, Tana,ka Y, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis:current evidence and future directions. Ann Rheum Dis. 2016;75:1428-1437. doi:10.1136/annrheumdis-2016-20920
  29. Jorgensen TS, Tarp S, Furst DE, et al. Added-value of combining methotrexate with a biological agent compared to biological monotherapy in patients with rheumatoid arthritis:a systemic review and meta-analysis of randomized trials. Ann Rheum Dis. 2015;74 (Suppl 2):239. doi:10.1136/annrheumdis-2015-eular.3396
  30. Buckley F, Finckh A, Huizinga TWJ, et al. Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs:a network meta-analysis. J Man Care Spec Pharm. 2015;21:409-423. doi:10.18553/jmcp.2015.21.5.409
  31. Nasonov E.L. Primenenie rituksimaba pri revmatoidnom artrite. V kn: Anti-V kletochnaya terapiya v revmatologii: fokus na rituksimab. Pod redaktsiei E.L. Nasonova. Moskva. «IMA-PRESS» 2011, str. 55-93.
  32. Bredermeier M, de Oliveira FK, Rocha CM. Low-versus high-dose rituximab for rheumatoid arthritis:a systemic review and meta-analysis. Arthritis Care Res. 2014;66:228-235. doi:10.1002/acr.22116
  33. Nasonov EL, Zonova EV, Ivanova O.N, i soavt. Rezul'taty sravnitel'nogo klinicheskogo issledovaniya III fazy preparatov rituksimaba (Atsellbiya i Mabtera) pri revmatoidnom artrite (issledovanie BIORA). Nauchno-prakticheskaya revmatologiya. 2016;54(4):prinyata k pechati.
  34. Nasonov EL. Abatatsept pri revmatoidnom artrite: novaya forma, novye mekhanizmy, novye vozmozhnosti. Nauchno-prakticheskaya revmatologiya. 2015;53:522-541. doi:10.14412/1995-4484-2015-522-541
  35. Nasonov EL, Aleksandrova EN, Avdeeva AS, Panasyuk EYu. Ingibitsiya interleikina 6 — novye vozmozhnosti farmakoterapii immunovospalitel'nykh revmaticheskikh zabolevanii. Nauchno-prakticheskaya revmatologiya. 2013;51:4216-427. doi:10.14412/1995-4484-2013-1254
  36. Nasonov EL. Novye podkhody k farmakoterapii revmatoidnogo artrita: tofatsitinib. Nauchno-prakticheskaya revmatologiya. 2014;52:209-221. doi:10.14412/1995-4484-2014-209-221
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.